Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025 Phase 2a clinical trial of GH001 in postpartum depression on track for expected completion in Q3 2024 Cash, cash equivalents, other financial assets and marketable securities of $214.0 million expected to provide cash runway... Read More